Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Read more about Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
Impact of imaging measurements on response assessment in glioblastoma clinical trials. Read more about Impact of imaging measurements on response assessment in glioblastoma clinical trials.
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Read more about Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Read more about Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.
Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Read more about Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
The epidemiology of glioma in adults: a "state of the science" review. Read more about The epidemiology of glioma in adults: a "state of the science" review.
DISTINCT AND SEPARABLE ROLES FOR HISTONE METHYLTRANSFERASE EZH2 IN NEUROGENIC ASTROCYTES. Read more about DISTINCT AND SEPARABLE ROLES FOR HISTONE METHYLTRANSFERASE EZH2 IN NEUROGENIC ASTROCYTES.
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Read more about A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Read more about Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.
Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure". Read more about Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure".
